MLSS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MLSS is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has a mildly constructive pre-market move, but the overall setup is weak: technicals are still bearish, insiders are heavy sellers, and there is no strong Intellectia buy signal. The business update is improving, but the latest quarter still missed revenue expectations and the company remains small, low-liquidity, and speculative. For an impatient investor who does not want to wait for a better entry, this is still not an attractive buy today.
Current pre-market price is 0.3483, up 3.82%, but the broader technical picture is not bullish. MACD histogram is negative and expanding, which suggests downside momentum is still present. RSI_6 at 37.02 is weak but not oversold enough to confirm a reversal. Moving averages are converging, indicating compression rather than a confirmed breakout. Price is below the pivot level of 0.39 and only slightly above support at 0.321, so the stock is trading near support but has not reclaimed resistance. The candlestick-pattern model also shows a negative near-term bias, with a 40% chance of -1.39% next day and only modest upside over the next week and month.
["Cost reduction of over 30% year-over-year, helping narrow losses", "CompuFlow medical revenue more than doubled year-over-year", "Company reaffirmed 2026 revenue guidance of $9.8 million to $10.2 million", "Most delayed orders from global conflict have now shipped in Q2", "Improved liquidity management with about $1.2 million in cash as of March 31, 2026"]
["Q1 GAAP EPS was -$0.01 and revenue of $2.16 million missed expectations", "Revenue declined 3.1% year-over-year in the latest quarter", "Insiders are selling heavily, with selling up 2723.48% over the last month", "Hedge funds are neutral with no significant accumulation trend", "No recent congress trading data and no political buying catalyst", "No Intellectia AI Stock Picker signal and no recent SwingMax buy signal", "Stock remains below key pivot resistance and technical momentum is still negative"]
Latest quarter: Q1 2026. Milestone Scientific reported revenue of $2.16 million and GAAP EPS of -$0.01. Revenue declined 3.1% year-over-year and came in below expectations, but management highlighted a more than 30% reduction in costs, which narrowed losses and improved flexibility. The company also reported approximately $1.2 million in cash as of March 31, 2026 and reaffirmed FY26 revenue guidance of $9.8 million to $10.2 million, with a target of cash flow breakeven by early 2027. Overall, the quarter was mixed: weak top-line growth, but better cost control and a clearer roadmap.
Recent analyst trend and price-target data were not provided, so there is no evidence of a positive analyst revision cycle. Based on the available Wall Street-style fundamentals, the pros are improving cost discipline, better product traction in CompuFlow, and reaffirmed revenue guidance. The cons are a revenue miss, continued losses, small cash balance, and insider selling. Wall Street would likely view MLSS as a speculative turnaround story rather than a high-conviction buy.
